Cover image for Vol. 65 Issue 12

Edited By: Bruce R. Ransom and Helmut Kettenmann

Impact Factor: 5.997

ISI Journal Citation Reports © Ranking: 2015: 25/256 (Neurosciences)

Online ISSN: 1098-1136

Recently Published Issues

See all

Quick Links

2016 Impact Factor:
GLIA is pleased to announce its new Impact Factor is 6.2!

2017 Release of Journal Citation Reports®. Source: Thomson Reuters 2016 Citation Data

Recently Published Articles

  1. Epilepsy and astrocyte energy metabolism

    Detlev Boison and Christian Steinhäuser

    Version of Record online: 17 OCT 2017 | DOI: 10.1002/glia.23247

    Thumbnail image of graphical abstract
    • Perturbations in astroglial metabolism play a major role in pathogenesis and pathophysiology of epilepsy.
    • Metabolic therapies, such as ketogenic diet therapy, restore glial metabolism as rational approach for seizure control.
  2. Microglial-induced Müller cell gliosis is attenuated by progesterone in a mouse model of retinitis pigmentosa

    Sarah L Roche, Ana M Ruiz-Lopez, Jennifer N Moloney, Ashleigh M Byrne and Thomas G Cotter

    Version of Record online: 16 OCT 2017 | DOI: 10.1002/glia.23243

    Thumbnail image of graphical abstract

    Norgestrel, a progesterone analogue, combats Müller cell gliosis in the rd10 retina. Norgestrel reduces gliosis by alleviating harmful microglial cytokine release and limiting the availability of the transcription factor pSTAT3, in Müller glia.

  3. Ulk4 deficiency leads to hypomyelination in mice

    Min Liu, Ping Xu, Zhenlong Guan, Xiaohong Qian, Peter Dockery, Una Fitzgerald, Timothy O'Brien and Sanbing Shen

    Version of Record online: 16 OCT 2017 | DOI: 10.1002/glia.23236

    Thumbnail image of graphical abstract

    Main Points

    • A Ser/Thr Kinase Ulk4 regulates myelination, which is reduced by half in Ulk4 mutant;
    • Myelin transcriptome is the most significant pathway altered in the mutant genome;
    • ULK4 may become a novel therapeutic target for hypomyelination diseases.
  4. Cellular and molecular characterization of IDH1-mutated diffuse low grade gliomas reveals tumor heterogeneity and absence of EGFR/PDGFRα activation

    S. Azar, N Leventoux, C Ripoll, V. Rigau, C. Gozé, F. Lorcy, L. Bauchet, H. Duffau, P. O. Guichet, B. Rothhut and J. P. Hugnot

    Version of Record online: 13 OCT 2017 | DOI: 10.1002/glia.23240

    Thumbnail image of graphical abstract

    IDH1-mutated astrocytoma and oligodendroglioma cells express both common (Olig1/2, Nkx2.2, EGFR, LIFR, MAG, NOGO-A) and preferentially-expressed proteins (Sox8, Sox9, MYT1, PTPRZ1, PDGFRα, Dcx). EGFR and PDGFRα are not activated in these tumors.

  5. Immunization with α-synuclein/Grp94 reshapes peripheral immunity and suppresses microgliosis in a chronic Parkinsonism model

    Javier Villadiego, Adahir Labrador-Garrido, Jaime M. Franco, Magdalena Leal-Lasarte, Erwin J. De Genst, Christopher M. Dobson, David Pozo, Juan J. Toledo-Aral and Cintia Roodveldt

    Version of Record online: 11 OCT 2017 | DOI: 10.1002/glia.23237

    Thumbnail image of graphical abstract

    α-synuclein/Grp94 vaccination, either by splenocytes adoptive transfer or by direct immunization, supports a unique Th1/immune-regulatory mixed profile leading to the first report of suppressed chronic microgliosis in a mouse model of parkinsonism.